United States: DOJ's New Corporate Compliance Evaluation Guidance and the Potential Impact on Life Sciences Companies

Previously Recorded on September 18, 2019

Earlier this year, the Criminal Division of the U.S. Department of Justice (DOJ) issued updated guidance for white-collar prosecutors on evaluating the effectiveness and adequacy of corporate compliance programs (DOJ Compliance Guidance.)  

In this webinar, Matthew Wetzel, Senior Counsel, Akin Gump, will discuss key considerations and updates for life sciences companies to help assess your compliance program. For additional resources, Akin Gump has developed a brochure to summarize DOJ’s guidance in a checklist format.

You will learn:

  • Why DOJ issued updated guidance on compliance programs;
  • How medical technology makers can use this guidance in their own compliance efforts; and
  • How this guidance serves as a positive support for private sector fraud prevention

Matthew Wetzel is an experienced health care lawyer and advocate, providing regulatory, fraud and abuse, coverage and payment, transparency, and compliance counseling to medical device and diagnostics manufacturers, pharmaceutical and biotech companies, and other health care and life sciences organizations.

Prior to joining Akin Gump, Matt served as vice president and deputy general counsel of the Advanced Medical Technology Association (“AdvaMed”), the world’s largest trade association of medical device and diagnostics manufacturers.

Matt holds a J.D., Georgetown University Law Center, cum laude, 2004 and B.A., Georgetown University, magna cum laude, 2001.

Watch the Webinar

Webinar Resources